Anticipating the Next Step in the Management of ALK-Positive NSCLC

J Thorac Oncol. 2018 May;13(5):595-597. doi: 10.1016/j.jtho.2018.03.007.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Carcinoma, Non-Small-Cell Lung*
  • Crizotinib
  • Humans
  • Lung Neoplasms*
  • Nivolumab
  • Receptor Protein-Tyrosine Kinases

Substances

  • Nivolumab
  • Crizotinib
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases